| NEW! Following the breakthrough SHIFT trial results, ivabradine has been approved for use in heart failure patients Following the breakthrough SHIFT trial results, ivabradine has been approved for use in heart failure patients, which represents a major step forward in the management of these patients. The European Commission’s decision authorized the use of ivabradine in patients with chronic heart failure NYHA II to IV class with systolic dysfunction, in sinus rhythm, with heart rate 75 bpm and higher, in combination with standard therapy including β-blocker therapy or when β-blocker therapy is contraindicated or not tolerated. This approval brings promise of better prognosis and improved quality of life for a great number of patients with chronic heart failure. According to the ESC, there are 15 million heart failure patients out of a total population of 900 million in the 51 ESC member countries.1 SHIfT FAST FACTS Elevated heart rate is a significant marker for mortality and morbidity in cardiovascular diseases including heart failure…Read more » SHIfT MAIN RESULTS |
NEW RESULTS FROM THE ESC CONGRESS 2012 HELD IN MUNICH! Ivabradine reduces the risk of repeated hospitalization for worsening heart failure A new analysis from the SHIFT study explored the effect of Procoralan on total and recurrent heart failure hospitalizations. Results show that treatment with ivabradine, on a background of guidelines-based heart failure therapy, is associated with a substantial reduction in the likelihood of recurrent hospitalizations for worsening heart failure. This benefit can be expected to improve quality of life and to substantially reduce health care costs. NEW RESULTS PUBLISHED IN THE EUROPEAN JOURNAL OF HEART FAILURE! This analysis proves that the beneficial effect of Procoralan is similar in patients with or without baseline mineralocorticoid receptor antagonist treatment and thus extends Procoralan’s benefits to patients receiving neurohormonal modulation with multiple drugs (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists).
|
| 1-Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933-989. | |
